Am J Clin Exp Immunol 2012;1(1):20-27.

Review Article
Interleukin 13 and the evolution of asthma therapy

Gabriele Grünig, David B. Corry, Joan Reibman, Marsha Wills-Karp

Departments of Environmental Medicine and Medicine, NYU Langone Medical Center, Tuxedo, NY 10987, USA;
Departments of Medicine and Pathology and Immunology, the Michael E. DeBakey VA Medical Center, and the Biology of
Inflammation Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Medicine, NYU Langone
Medical Center, New York, NY 10016, USA; Department of Environmental Health Sciences, Johns Hopkins Bloomberg
School of Medicine, Baltimore, MD 21218, USA.

Received January 23, 2012; accepted March 5, 2012; Epub April 23, 2012; Published June 30, 2012

Abstract: This is a concise review on Interleukin (IL)-13 and the evolution of asthma therapy, from discovery of the
molecule, the identification of its pathogenic role in animal models of asthma, to the development of clinically successful
neutralizing agents.   The translational path from basic research to clinical application was not sequential as expected
but random with respect to the tools (molecular & cell biology, animal models, human studies) used and to the
application of academic versus industry research.   The experiences with the development of neutralizing anti-IL-13
reagents emphasize the need for inclusion of a biomarker assay in the clinical trials that both identifies individuals that
actually have aberrant expression of the pathway of interest and allows determining whether the target of interest is
neutralized. (AJCEI1201001).

Keywords: IL-13, asthma, therapy, biomarkers

Address all correspondence to:
Gabriele Grunig, DVM, PhD
57 Old Forge Road, Floor 1 Room 106
Tuxedo, NY 10987
Tel: 845 731 3669

David Corry, MD, PhD
One Baylor Plaza, M915D
Houston, TX 77030
Tel: 713 798 8740
AJCEI Copyright © 2012-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA